FDA Clearance Tracker · P160002-S006
VENTANA PD-L1(SP142) CDX ASSAY
Last checked: Nov 20, 2026Latest source record: Jul 2, 2018 (this decision)Source: openFDAMethods & limitations
Decided
Jul 2, 2018
Approved
Time to decision
18 days
Received Jun 14, 2018. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track
Device class
Class III
The decision
- FDA number
- P160002-S006
- Device name
- VENTANA PD-L1(SP142) CDX ASSAY
- Applicant
- Ventana Medical Systems, Inc.
- Applicant location
- Tucson, AZ
- Received
- Jun 14, 2018
- Decided
- Jul 2, 2018
- Decision
- Approved
- Supplement type
- Normal 180 Day Track
- Reason for supplement
- Labeling Change - Indications/instructions/shelf life/tradename
- Original approval
- P160002
Device type
- Device class
- Class III
- Specialty
- Laboratory Medicine & Pathology
FDA's approval statement
As written in FDA's record.
Approval for modifying the intended use of the VENTANA PD-L1(SP142). The VENTANA PD-L1 (SP142) Assay is a qualitative immunohistochemical assay using rabbit monoclonal anti-PD-L1 clone SP142 intended for use in the assessment of the PD-L1 protein in formalin-fixed, paraffin-embedded (FFPE) urothelial carcinoma and non-small cell lung cancer (NSCLC) tissue stained with OptiView DAB IHC Detection Kit and OptiView Amplification Kit on a VENTANA BenchMark ULTRA instrument. Determination of PD-L1 status is indication-specific, and evaluation is based on either the proportion of tumor area occupied by PD-L1 expressing tumor-infiltrating immune cells (% IC) of any intensity or the percentage of PD-L1 expressing tumor cells (% TC) of any intensity.PD-L1 expression in >= 5% IC determined by VENTANA PD-L1 (SP142) Assay in urothelial carcinoma tissue is indicated as an aid in identifying urothelial carcinoma patients for treatment with TECENTRIQ (atezolizumab).PD-L1 expression in >= 50% TC or >= 10% IC determined by VENTANA PD-L1 (SP142) Assay in NSCLC tissue may be associated with enhanced overall survival from TECENTRIQ (atezolizumab).See the TECENTRIQ® product label for PD-L1 expression cutoff values guiding therapy in specific clinical circumstances.This product is intended for in vitro diagnostic (IVD) use.
Source documents
Other decisions for Ventana Medical Systems, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- VENTANA HER2 Dual ISH DNA Probe CocktailPMA supplement
P190031-S016 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: Chromogenic In Situ Hybridization, Nucleic Acid Amplification, Her2/Neu Gene, Breast Cancer (NYQ) · Laboratory Medicine & Pathology
P990081-S060 · Decided Aug 25, 2026 · 153 days after receipt · Panel Track
Device type: SYSTEM, TEST, HER-2/NEU, IHC (MVC) · Laboratory Medicine & Pathology
P250031 · Decided Jun 12, 2026 · 298 days after receipt
Device type: Immunohistochemistry Assay, Antibody (SHF) · Laboratory Medicine & Pathology
5 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.